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Abstract 
 
Multiple sclerosis (MS) is an autoimmune disease of the central nerv-
ous system characterized by inflammatory demyelination and some 
axonal damage.  An overactive or dysfunctional immune response to 
self-antigen is believed to be the pathogenic mechanism and therefore 
the treatment of MS often involves immunosuppressive therapy.  Be-
cause of altered immune function in patients with MS, questions arise 
about risk of infections in this population and the safety and efficacy of 
common immunizations.  The risk of MS exacerbation with common 
infections and safety and efficacy of immunization are reviewed along 
with the available guidelines for use of vaccines in patients with MS. 
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Multiple sclerosis (MS) is an autoimmune 
disease of the central nervous system charac-
terized by inflammation mediated demye-
lination and also some axonal damage.  An 
overactive or dysfunctional immune response 
to self-antigen is the presumed pathogenic 
mechanism, much like any other autoim-
mune disorder.  Therefore, treatment of MS 
often involves immunosuppressive therapy.  
Because of altered immune function in pa-
tients with MS, questions arise about risk of 
infection in this population and the safety 
and efficacy of common immunizations. 
 
Are Infections More Common in MS? 
 
The traditional concepts of the pathophysiol- 
 
 
ogy of MS include T-lymphocyte activation 
by an inciting antigen.1  These activated T-
cells induce an inflammatory cascade and 
cell-mediated attack of central nervous sys-
tem myelin.  More recent studies exploring 
the immunology of MS have found abnor-
malities in both T-lymphocytes and B-
lymphocytes.  Since abnormal cell-mediated 
and humoral immunity play a role in the 
pathogenesis of disease, there may be higher 
susceptibility to infections in MS patients.  
However, despite the immune dysregulation 
evident in patients with MS, immunity 
against common viral and bacterial infections 
appears to be preserved.  The incidence of 
commonly occurring infectious diseases is 
not increased among MS patients.2-3  Howev-
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er, infection can trigger a relapse and it has 
been observed that there is increased inci-
dence of clinical relapse in MS patients asso-
ciated with infections.4-5  Therefore, immun-
ization is important for MS patients not only 
to prevent an infectious illness, but also to 
potentially prevent MS relapses. 
 
Can Vaccines Exacerbate MS Relaps-
es? 
 
There is a longstanding concern that immun-
ization may trigger MS activity in much the 
same way that vaccines reportedly trigger 
other autoimmune diseases such as Guillain-
Barre syndrome.6-8  Theoretically, by induc-
ing a heightened immune response against 
live attenuated viruses (e.g. measles and vari-
cella), inactive viruses (e.g. seasonal influen-
za and hepatitis A), or portions of viruses or 
bacteria (e.g. hepatitis B, HPV, and pneumo-
coccus); vaccines might also induce an ab-
normal immune response against self-
antigens.  Hepatitis-B vaccine has been of 
particular concern and both new cases and 
relapses of MS have been reported following 
its administration.9  However, several epide-
miologic studies have shown no relationship 
between the hepatitis B vaccine and either 
development of MS or MS relapses.10-12  An-
other inactive virus vaccine with potential 
implications for MS patients, because of its 
widespread use, is the seasonal influenza 
vaccine.  As with hepatitis B, there is no def-
inite increase of either occurrence of MS or 
MS relapse following the flu vaccination.  
One randomized, double-blind, placebo con-
trolled trial of influenza vaccine in MS pa-
tients found no significant differences in 
rates of relapse between those vaccinated and 
those receiving placebo.13  Another case-
control study found no association between 
MS relapses and recent vaccinations for in-
fluenza, hepatitis B, or tetanus.14  The evi-
dence is sparse regarding the risk of MS or 
MS relapse following immunization with live  
 
attenuated viruses, such as varicella, measles,  
smallpox, yellow fever, polio, BCG, or in-
tranasal influenza vaccine.  Overall there 
does not appear to be a heightened risk, but 
there are no large controlled studies to sup-
port this observation.15-16 
 
Are Vaccines Effective in MS? 
 
Apart from the risk of MS or MS relapse 
from vaccination is the issue of vaccine effi-
cacy in MS patients due to inherent immune 
system dysfunction.  Few studies have inves-
tigated this question and there is insufficient 
evidence to make a determination.13, 17  The 
antibody levels to viruses following vaccina-
tion are present in MS patients at similar lev-
els to healthy subjects.15  This suggests that 
vaccination is likely as effective in MS pa-
tients. 
 
How Does Immunosuppressive Therapy 
Affect Immunization in MS? 
 
Since the advent of effective therapies in the 
last two decades, most MS patients are now 
treated with immunomodulatory agents such 
as interferon-beta or glatiramer acetate.  A 
significant proportion of patients also re-
ceives one of the immunosuppressant medi-
cations such as corticosteroids, mitoxantrone, 
cyclophosphamide, azathioprine, mycophe-
nolate mofetil, or methotrexate.  Some may 
also be treated with monoclonal antibodies 
such as natalizumab, alemtuzumab, or rituxi-
mab that are targeted against specific T-
lymphocyte or B-lymphocyte antigens.  
There is a concern that immunosupression or 
modulation induced by these therapies may 
potentially increase the risk of infection fol-
lowing the administration of a vaccine partic-
ularly a live vaccine.  In general, all inacti-
vated virus vaccines are considered safe and 
effective for patients receiving any of these 
therapies (see Table 1); however, the vaccine 
might need to be readministered after im- 
 
18 
 
Cahill et al.: Immunization in Patients With Multiple Sclerosis
Neurol. Bull. 2: 17-21, 2010 
doi:10.7191/neurol_bull.2010.1020 
 
 
19 
Vaccine & Common Brand Name(s) Vaccine Type 
Safe for MS patients on immuno-
suppressive therapy?* 
MMR (measles/mumps/rubella) Live attenuated No 
Oral Polio (OPV) Live attenuated No 
Varicella (Zostavax®, Varivax®) Live attenuated No 
Inactive Polio Vaccine Inactivated YES 
Inactive Influenza Vaccine (Fluarix®) Inactivated YES 
Influenza Nasal Vaccine (FluMist®) Live attenuated No 
Influenza A H1N1 2009 Monovalent Vaccine Inactivated YES 
Influenza A H1N1 2009 Monovalent Vaccine, Live 
Intranasal 
Live attenuated No 
Diptheria/Tetanus/Pertussis (DTP, DTaP or dT, 
Tdap) (Adacel®, Boostrix®, Pediarix®, Daptacel®, 
Tripedia®, Infarix®, Pentacel®, Daptacel®) 
Toxoid YES 
Haemophilus influenza type B Hib (Hibirix®, Ac-
tHib®, PedVaxHib®) 
Component YES 
Hepatitis B (Recombivax-HB®, Engerix-B®, Twin-
rix®) 
Component YES 
Hepatitis A (Havrix®, Vaqta®, Twinrix®) Inactivated YES 
Pneumococcal vaccine (Pneumovax 23®, Prevnar®) Component YES 
Meningococcal vaccine (Menactra®, Menveo®) Toxoid Conjugate YES 
Yellow Fever vaccine (Yf-Vax®) Live attenuated No 
Typhoid vaccine (Vivotif®) Live attenuated No 
Human Papilloma Virus (HPV) (Gardasil®) Component YES 
Tetanus Toxoid Toxoid YES 
Rotavirus (Rotateq®) Live attenuated No 
Table 1 is compiled and adapted from the Centers for Disease Control website and the Nation-
al MS Society website.  Vaccine common brand names obtained from MICROMEDEX.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
does not include patients taking monotherapy interferon-beta or glatiramer acetate who should be vac-
cinated as per CDC guidelines. 
 
mune competence is restored.  Live attenu-
ated virus vaccines, on the other hand, por-
tend a higher potential risk of infection and 
complication for patients on immunosuppres-
sant medications including steroids.18  There-
fore, in general, live attenuated vaccines are 
avoided in MS patients on chronic immuno-
suppressive therapy; however there is no  
 
firm evidence to support this approach.  Ad-
ditionally, there is issue of effectiveness of 
common immunizations in MS patients re-
ceiving immunosuppressive therapy.  The 
live attenuated virus vaccines are not as ef-
fective following periods of immunosupres-
sion and should not be administered for three 
months following treatment with immuno-
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suppressant medications.  In contrast to con-
cerns about decreased efficacy of live attenu-
ated vaccines in immunosuppressed patients, 
immunomodulatory therapy with interferon 
or glatiramer acetate does not appear to inter-
fere with efficacy of live vaccines and these 
vaccines are safe in patients on immunomod-
ulatory therapy alone, without concomitant 
immunosuppressant medications. 
 
Current Recommendations for Immun-
ization in MS Patients 
 
Based on available evidence, the Immuniza-
tion Panel of the Multiple Sclerosis Council 
for Clinical Practice Guidelines has made 
some general recommendations.  According 
to these, inactivated influenza vaccine, hepa-
titis B, varicella, tetanus, and other vaccines 
should be used per Centers for Disease Con-
trol (CDC) indication for these vaccines.19  
The pneumococcal vaccine is indicated for 
patients with compromised pulmonary func-
tion, such as wheelchair-dependant or bed-
bound patients, as these patients are more 
prone to pneumonia.  There is a divided 
opinion regarding usefulness of influenza 
vaccine in patients with MS who otherwise 
do not meet the CDC indication criteria for 
flu vaccine.  The panel recommends that the 
potential risks and benefits of vaccination in 
these cases should be discussed with the indi-
vidual patient.  However since the seasonal 
flu is quite common and can precipitate an 
exacerbation, it is appropriate to offer influ-
enza immunization to all MS patients unless 
there are any contraindications.  Similarly, 
deactivated H1N1 (Swine Flu) vaccine is 
generally indicated (per CDC guidelines) for 
persons aged 25-64 who have medical condi-
tions that put them at higher risk for influen-
za-related complications.  A person with ad-
vanced MS or someone with less severe dis-
ease with reduced pulmonary function is 
considered at risk for such complications and 
a good candidate for the de-activated H1N1 
20 
vaccine.  For persons with less severe MS, 
the decision regarding H1N1 vaccine should 
be made in discussion with their physician 
and neurologist. 
  
Conclusion 
 
Overall, vaccines are safe and effective for 
patients with MS and should be offered to 
MS patient based on general CDC guide-
lines.  For patients on immunosuppressant 
medications, live attenuated vaccines should 
be avoided while patients are on therapy and 
for three months after treatment.  As the in-
fluenza season approaches, MS patients and 
their physicians should consider the influen-
za vaccine a safe and effective option unless 
there are specific contraindications. 
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